The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

(2019) Jeffrey W. Chen et al.   ANNALS OF PHARMACOTHERAPY

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study

(2019) Elizabeth Thiele et al.   EPILEPSIA

Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America

(2018) Ran Abuhasira et al.   European Journal of Internal Medicine

Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited

(2018) C. S. Constantinescu et al.   EUROPEAN JOURNAL OF NEUROLOGY

Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis

(2018) M. Sorosina et al.   EUROPEAN JOURNAL OF NEUROLOGY

Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

(2018) Jolana Markovà et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

(2018) Eric P. Baron   HEADACHE

Cannabis and the Anxiety of Fragmentation—A Systems Approach for Finding an Anxiolytic Cannabis Chemotype

(2018) Brishna S. Kamal et al.   Frontiers in Neuroscience

Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients

(2017) Sebastian Schimrigk et al.   EUROPEAN NEUROLOGY

Terpene synthases from Cannabis sativa

(2017) Judith K. Booth et al.   PLoS One

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis

(2017) Guido van Amerongen et al.   CLINICAL THERAPEUTICS

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation

(2017) Atheer Zgair et al.   Scientific Reports

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity

(2016) Michael Haupts et al.   EUROPEAN NEUROLOGY

Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice

(2016) Patrick Vermersch et al.   EUROPEAN NEUROLOGY

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

(2016) F Patti et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray

(2016) Giovanna Squintani et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

(2016) Tilden Etges et al.   Therapeutics and Clinical Risk Management

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation

(2015) Sumner Burstein   BIOORGANIC & MEDICINAL CHEMISTRY

Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study

(2015) Maria Trojano et al.   EUROPEAN NEUROLOGY

Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis

(2015) Letizia Leocani et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study

(2015) Laura Ferrè et al.   NEUROLOGICAL SCIENCES

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation

(2015) Margherita Russo et al.   NEURAL PLASTICITY

Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol

(2015) Nina L. Cluny et al.   PLoS One

What’s new in multiple sclerosis?

(2014) Lilia G Dimitrov et al.   BRITISH JOURNAL OF GENERAL PRACTICE

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain

(2013) Radu Tanasescu et al.   Expert Opinion on Drug Metabolism & Toxicology

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

The immune modifying effects of amino acids on gut-associated lymphoid tissue

(2013) Megan R Ruth et al.   Journal of Animal Science and Biotechnology

The Endocannabinoid System and the Brain

(2012) Raphael Mechoulam et al.   Annual Review of Psychology

Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects

(2012) Linda E. Klumpers et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

(2012) Michael G. Serpell et al.   JOURNAL OF NEUROLOGY

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

(2012) R. M. Langford et al.   JOURNAL OF NEUROLOGY

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

(2012) John Peter Zajicek et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

(2011) Ethan B Russo   BRITISH JOURNAL OF PHARMACOLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

(2011) Jaume Sastre-Garriga et al.   Expert Review of Neurotherapeutics

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

Plasma Cannabinoid Pharmacokinetics following Controlled Oral  9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration

(2010) E. L. Karschner et al.   CLINICAL CHEMISTRY

Complementary and Alternative Medicine for Pain: An Evidence-based Review

(2010) Nadya M. Dhanani et al.   Current Pain and Headache Reports

The changing demographic pattern of multiple sclerosis epidemiology

(2010) Nils Koch-Henriksen et al.   LANCET NEUROLOGY

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Synergy research: Approaching a new generation of phytopharmaceuticals

(2009) H. Wagner et al.   PHYTOMEDICINE

Beneficial effects of aCannabis sativaextract treatment on diabetes-induced neuropathy and oxidative stress

(2009) Francesca Comelli et al.   PHYTOTHERAPY RESEARCH

Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol

(2008) Hamish Redmond Ross et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved

(2008) Francesca Comelli et al.   PHYTOTHERAPY RESEARCH

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid

(2007) P. Massi et al.   JOURNAL OF NEUROCHEMISTRY